California Institute for Quantitative Biosciences

Juvena Therapeutics Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases

Retrieved on: 
Tuesday, November 8, 2022
Research, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Erythropoietin, B cell, Harvard University, Felicis Ventures, Proteomics, Myotonic dystrophy, Engineering, FDA, DeepMind, Horizon, Foundation for the National Institutes of Health, VC, University of California, Berkeley, Horizons Ventures, Insulin, Growth hormone, Systems biology, Venture capital, Series A round, Impossible Foods, Regenerative medicine, National Institute, Biomarker, Drug discovery, Intersection, California Institute for Regenerative Medicine, Stanford University, Regeneration, Doctor of Philosophy, Ageing, Investment, Protein, Protein engineering, Biology, Degenerative disease, California Institute for Quantitative Biosciences, Therapy, SVP, Compound, Siri, Map, Mubadala Investment Company, Pharmaceutical industry, Vaccine, Spotify

The new funding will power the expansion of Juvenas drug discovery platform and advance the companys biologics pipeline targeting chronic and age-related diseases.

Key Points: 
  • The new funding will power the expansion of Juvenas drug discovery platform and advance the companys biologics pipeline targeting chronic and age-related diseases.
  • Secreted proteins are a proven class of biologics with tremendous therapeutic potential, as they regulate tissue repair and regeneration, organ development, and immune response to disease.
  • These limitations have constrained biopharmas approach to studying the role of secreted proteins only as drug targets or biomarkers, rather than drug agents themselves.
  • Juvena Therapeutics is a biotech company accelerating the development of therapeutics by unlocking the therapeutic potential of secreted proteins.

Immune-Onc Therapeutics Appoints Two New Members to its Board of Directors

Retrieved on: 
Tuesday, November 8, 2022
Biotechnology, Pharmaceutical, Health, Oncology, National, LILRB4, LAIR1, LILRB2, White blood cell, Industry, Onyx Pharmaceuticals, Case Western Reserve University, Patient, Lymphatic system, Doctor of Philosophy, ILT4, GSK, NCI, Board, Leukemia & Lymphoma Society, Cancer, Immunotherapy, California Institute for Quantitative Biosciences, Chronic myelomonocytic leukemia, Regenerative medicine, University of California, Davis, UCSF, California Institute for Regenerative Medicine, Drug development, University, CIRM, National Cancer Institute, NIH, Board of directors, University of California, San Francisco, OncoMed, Leadership, Genentech, Medicine, Amgen, Record, Leukemia, Biology, Acute myeloid leukemia, BeiGene, LLS, Research, Therapy, Tumor microenvironment, AML, CMML, ILT3, Regeneron Pharmaceuticals, Cytokine, Vaccine, Pharmaceutical industry

"Austin and Barbara have a deep understanding of the discovery and development process for breakthrough cancer therapies, experience that both complements and expands the expertise of our Board.

Key Points: 
  • "Austin and Barbara have a deep understanding of the discovery and development process for breakthrough cancer therapies, experience that both complements and expands the expertise of our Board.
  • Immune-Oncs pioneering role in developing myeloid checkpoint inhibitors as next generation immunotherapies has impressed me, said Dr. Gurney.
  • Austin Gurney, Ph.D. is a biotech industry veteran with over two decades of experience in the discovery and development of novel therapeutics.
  • Immune-Oncs focused platform approach has led to the development of several promising therapeutics across various stages of development.

Rewind Therapeutics Appoints Irene Knuesel, PhD, as Chief Scientific Officer

Retrieved on: 
Wednesday, October 19, 2022
Rewind, Nerve injury, Disease, Therapy, CSO, PD, Swiss Federal Institute of Aquatic Science and Technology, Science, Multiple sclerosis, Optic neuritis, Patient, Total survey error, Research, HIV disease progression rates, University, Company, Drug discovery, Doctor of Philosophy, Industry, Remyelination, CNS, Demyelinating disease, Head, University of Zurich, California Institute for Quantitative Biosciences, Swiss Federal Institute of Technology, Molecular neuroscience, Neurodegeneration, PMV, Pharmaceutical industry

Leuven, Belgium, October 19, 2022 --- Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that Irene Knuesel, PhD, PD, has been appointed as the Company´s Chief Scientific Officer.

Key Points: 
  • Leuven, Belgium, October 19, 2022 --- Rewind Therapeutics , a company developing first-in-class treatments for demyelination-associated diseases, today announced that Irene Knuesel, PhD, PD, has been appointed as the Companys Chief Scientific Officer.
  • "We warmly welcome Irene as our new CSO and are excited that she joins Rewind," said Anja Harmeier, Chief Executive Officer at Rewind Therapeutics.
  • Our goal is to progress to a clinical-stage portfolio company and we know Irene will play a significant role in advancing Rewind."
  • "Rewind Therapeutics has built a great team and comprehensive expertise in remyelination," said Irene Knuesel, Chief Scientific Officer at Rewind Therapeutics.

Lisata Therapeutics’ Director and Scientific Founder of the CendR Platform™ Technology, Erkki Ruoslahti, M.D., Ph.D., Receives 2022 Albert Lasker Basic Medical Research Award

Retrieved on: 
Thursday, September 29, 2022
American Academy, Lasker Award, Safety, Canada Gairdner International Award, Center, City of Hope National Medical Center, Biology, Patient, Perseverance, Nasdaq, Sanford Burnham Prebys Medical Discovery Institute, Research, Disease, University of California, Santa Barbara, National Academy of Medicine, Life, DRS, CD34, Japan Prize, University of Helsinki, Tumor microenvironment, University of Turku, RGD, National Academy of Inventors, Integrin, California Institute for Quantitative Biosciences, Director, European, Neoplasm, Physiology, City, European Molecular Biology Organization, Board of directors, Tissue, GLOBE, Peptide, Health, Therapy, Thrombosis, National academy, CendR, Japan, Pancreatic cancer, Cell adhesion, Nanomedicine, Survival, Cancer, Cell, Medical research, RNA, Heart, University, Pharmaceutical industry, Technology, Science

The Albert Lasker Basic Medical Research Award is one of the highly competitive and distinguished international prizes for medical science awarded by the Lasker Foundation.

Key Points: 
  • The Albert Lasker Basic Medical Research Award is one of the highly competitive and distinguished international prizes for medical science awarded by the Lasker Foundation.
  • Lisata and its collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics.
  • Lisata is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively.
  • In addition, Lisata also has clinical development programs based on its autologous CD34+ cell therapy technology platform.

Reliance New Energy Limited to invest in Caelux Corporation

Retrieved on: 
Friday, September 23, 2022
104th Wisconsin Legislature, Temperature, Reliance Industries, Khosla Ventures, California Institute for Quantitative Biosciences, Efficiency, LinkedIn, Partnership, Industry, USD, Forbes, CEO, Fortune Global 500, Technology, Hydrogen, Private sector, Architecture, Silicon, Metropolitan area, Lists of companies, Ecosystem, INR, Fortune 500, Research, Marketing, Leg, Airline, Renewable energy, California Institute of Technology

MUMBAI, India, Sept. 23, 2022 /PRNewswire/ -- Reliance New Energy Limited ("RNEL"), a wholly owned subsidiary of Reliance Industries Ltd ("Reliance"), has today signed definitive agreements to invest in Caelux Corporation ("Caelux"), a company headquartered in Pasadena, California, in the United States of America, engaged in the development of perovskite-based solar technology. RNEL will invest USD 12 million to acquire 20% stake in Caelux.

Key Points: 
  • MUMBAI, India, Sept. 23, 2022 /PRNewswire/ -- Reliance New Energy Limited ("RNEL"), a wholly owned subsidiary of Reliance Industries Ltd ("Reliance"), has today signed definitive agreements to invest in Caelux Corporation ("Caelux"), a company headquartered in Pasadena, California, in the United States of America, engaged in the development of perovskite-based solar technology.
  • RNEL will invest USD 12 million to acquire 20% stake in Caelux.
  • RNEL and Caelux have also entered into a strategic partnership agreement for technical collaboration and commercialization of Caelux's technology.
  • Through this investment and collaboration, Reliance will be able to produce more powerful and lower cost solar modules leveraging Caelux's products.

Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access

Retrieved on: 
Tuesday, September 13, 2022
Cardiology, Biotechnology, Pharmaceutical, Medical Supplies, Oncology, Health, Genetics, Other Health, Laboratory, Investor, Doctor of Philosophy, California Institute for Quantitative Biosciences, Twitter, FDA, Research, NanoString Technologies, Health, Partnership, Rutgers University, Forward-looking statement, Lung cancer, Patient, Degenerative disease, Physician, Pulmonology, Annual report, CLIA, Leadership, Diagnosis, General manager, Lung, Multimedia, University, School, Medical device, Pharmaceutical industry, Illumina, Biochemistry, Technology

Veracyte, Inc. (Nasdaq: VCYT) announced today that John Leite, Ph.D., has joined the company as senior vice president and general manager of Pulmonology & Market Access.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) announced today that John Leite, Ph.D., has joined the company as senior vice president and general manager of Pulmonology & Market Access.
  • View the full release here: https://www.businesswire.com/news/home/20220913005446/en/
    Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access (Photo: Business Wire)
    Veracyte is deeply committed to pulmonology where we believe there are significant unmet needs in lung cancer and other respiratory diseases that our tests can uniquely address, said Dr. Nova.
  • Dr. Leite joined Veracyte from Intervenn, a private-stage diagnostics company where he was chief business officer, responsible for the companys commercial, partnership and market access strategy.
  • Veracyte, the Veracyte logo, Percepta and Envisia are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries.

Where Computation and Experimentation Collide

Retrieved on: 
Wednesday, September 7, 2022
Cardiovascular disease, Machine learning, University of California, San Francisco, Degenerative disease, RNA, Cancer, Rupture, UC, Research, Gene, Gladstone Institutes, Genetics, SAN, Boston Children's Hospital, Doctor of Philosophy, Time, Communication, Disease, Heart, Mouse, Tissue, Hope, MIT, Cardiomyopathy, Department, California Institute of Technology, Gene expression, Cell, Chromatin, Harvard University, Deep learning, MD, Map, Dana–Farber Cancer Institute, Biology, Architecture, Hospital, California Institute for Quantitative Biosciences, Aortic aneurysm, UCSF, Aorta, Clinical trial, Broad Institute, University, Eric Davidson, Life, IPS, Media contacts database, Patient, Coffee, Medical imaging, Pharmaceutical industry, Medicine, Vaccine, Surveying, William Ewart Gladstone, Technology, Pediatrics

SAN FRANCISCO, Sept. 6, 2022 /PRNewswire/ -- In order for our hearts to form correctly and keep us thriving, hundreds of genes must act together in complex networks. If part of a network malfunctions, cardiovascular disease may arise.

Key Points: 
  • Now, after 5 years as a resident in pediatric genetics at Boston Children's Hospital, Theodoris has returned to San Francisco.
  • In addition to her new role at Gladstone, she is also joining UCSF as an assistant professor in the Department of Pediatrics.
  • Drugs that treat disease by targeting individual dysfunctional genes already exist for many illnesses, especially different types of cancer.
  • This union of computation and experimentation surfaced a promising drug candidate that successfully prevented calcific aortic valve disease in mice.

Arkose Labs Ranks in Top 500 of Inc. 5000 for Second Consecutive Year, Achieving Three-year Revenue Growth Rate of 1,479.57%

Retrieved on: 
Tuesday, August 16, 2022
Industry, Name, CEO, ROI, Technology, Growth, Database, Fear, Facebook, Microsoft, California Institute for Quantitative Biosciences, Under Armour, SAN, Partnership, Inc., COVID-19, Chobani, Solution, Deloitte, Video game, Airline

SAN MATEO, Calif., Aug. 16, 2022 /PRNewswire/ -- Arkose Labs, the global leader in fraud deterrence and account security, announced today that it made the Inc. 5000 2022 list for a second consecutive year with a revenue growth rate of 1,479.57 percent. The Inc. 5000 list is the most prestigious ranking of the fastest-growing private companies in America and represents a one-of-a-kind look at the most successful companies within the economy's most dynamic segment—its independent businesses. Facebook, Chobani, UnderArmour, Microsoft, Patagonia, and many other well-known names gained their first national exposure as honorees on the Inc. 5000.

Key Points: 
  • Facebook, Chobani, UnderArmour, Microsoft, Patagonia, and many other well-known names gained their first national exposure as honorees on the Inc. 5000.
  • Among the top 500, of which Arkose Labs is one, the average median three-year revenue growth rate soared to 2,144 percent.
  • "Every day I'm meeting with and listening to our customers and prospective customers," said Arkose Labs Chief Revenue Officer Richard Dufty .
  • Companies on the 2022 Inc. 5000 are ranked according to percentage revenue growth from2018 to 2021.

Frazier Healthcare Partners Announces Amy DuRoss as Senior Advisor

Retrieved on: 
Monday, August 1, 2022
General Health, Finance, Health, Professional Services, Managed Care, CA, Investment, GE Ventures, Genomics, California Institute for Regenerative Medicine, Gaps, CEO, CIRM, Gene, The Co Founder, Center for Cell and Gene Therapy, California Institute for Quantitative Biosciences, Philosophy, Cell, CGT, Senior, Thermo Fisher Scientific, Senior advisor, Frank DuRoss, Therapy, Frazier Healthcare Partners, Life Technologies, Growth, Regenerative medicine, Financial services, Pharmaceutical industry, Navigenics

Frazier Healthcare Partners, a leading private equity and venture capital firm focused exclusively on the healthcare industry, is pleased to announce that Amy DuRoss has joined the firms Growth Buyout team as a Senior Advisor.

Key Points: 
  • Frazier Healthcare Partners, a leading private equity and venture capital firm focused exclusively on the healthcare industry, is pleased to announce that Amy DuRoss has joined the firms Growth Buyout team as a Senior Advisor.
  • Amy is a great fit with our firms culture, and we are fortunate to have her as a Senior Advisor.
  • Founded in 1991, Frazier Healthcare Partners is a leading private equity firm focused exclusively on the healthcare sector.
  • For more information about Frazier Healthcare Partners, visit www.frazierhealthcare.com .

Global Smart Pills Market Report 2022-2027: Development of Addressable Transmitters Operated as Magnetic Spins Showing High Potential

Retrieved on: 
Tuesday, July 26, 2022
MRI, Brain, Diagnosis, Magnetic spin vortex disc, Degenerative disease, Esophagus, Hospital, Temperature, Stomach, Silicon, Research, Field line, Health, California Institute for Quantitative Biosciences, PH, Gastrointestinal tract, Patient, Blood, Endoscopy, Pressure, Google Images, Magnetic resonance imaging, Growth, Capsule endoscopy, Medical imaging, California Institute of Technology, Technology

DUBLIN, July 26, 2022 /PRNewswire/ -- The "Global Smart Pills Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 26, 2022 /PRNewswire/ -- The "Global Smart Pills Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The smart pills market consists of the sales of capsule-sized ingestible medical devices with small embedded electronic products such as sensors, cameras, patches, and trackers.
  • The high cost of smart pills associated with technological advancement will act as a restraint to the market growth.
  • Extensive research and development are being carried out on the use of miniature chips such as Addressable Transmitters Operated as Magnetic Spins (ATOMS) which can be used as smart pills.